Role of Childhood Aerobic Fitness in Successful Street Crossing30 Oct 2022 08:54
Big thanks for the regular posters on here but M. McNulty is just ...wow!
I was just reading this:
https://www.lovemoney.com/galleries/155901/friday-28-october-2022s-biggest-uk-stock-market-risers-and-fallers?page=1
(another “fool” article) thinking, what money are we talking about in early-stage bio companies?
Started to look for some examples on the net but then, EUREKA!
“Knowing “ Myles, he MUST have covered this already.
Looking into his notes and
Voila: “
“Rather, we will simply highlight a selection of recent transactions in the targeted cancer therapy space (including immunotherapies and antibody-drug conjugates (‘ADC’)), so as to provide some insight into the value attributed to these classes of drugs by Big Pharma, even at relatively early stages of clinical development. Collaborations: - Genentech and Bicycle Therapeutics collaboration (up to $1.7 billion) 9 In February 2020, Genentech (a member of Roche Group) and Bicycle Therapeutics announced an exclusive strategic collaboration to develop and commercialise Bicycle®-based targeted immunotherapies against multiple targets. The collaboration involves the discovery and pre-clinical development of novel therapies, and does not include any candidate from Bicycle’s existing and wholly owned pipeline. Bicycle received a $30 million upfront payment. The upfront payment and potential discovery, development, regulatory and commercial-based milestone payments could total up to $1.7 billion. - AstraZeneca and Daiichi Sankyo collaboration (up to $6 billion) 10 In July 2020, AstraZeneca and Daiichi Sankyo Company entered into a new global development and commercialisation agreement for DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (‘TROP2’)-directed antibody-drug conjugate. Using Daiichi Sankyo’s proprietary DXd ADC technology, DS-1062 is designed to deliver chemotherapy selectively to cancer cells and to reduce systemic exposure. AstraZeneca would pay Daiichi Sankyo an upfront fee of $1bn; and pay additional conditional amounts of up to $1bn for the successful achievement of regulatory approvals and up to $4bn for sales-related milestones. At the time of the agreement, Daiichi Sankyo had only just commenced enrolling patients for a Phase 1 trial. Neither safety nor efficacy for DS-1062 had been established. - Bristol Myers Squibb and Eisai collaboration (up to $3.1 billion) 11 In June 2021, BMS and Eisai entered into a global strategic collaboration agreement for the co-development and co-commercialisation of Eisai’s first antibody-drug conjugate, MORAb-202. The ADC combines Eisai’s in-house developed anti-folate receptor alpha (FRa) antibody, and Eisai’s anticancer agent eribulin, using an enzyme cleavable linker. At the time, MORAb-202 was being tested in two studies: a Phase 1 study in Japan and a Phase 1/2 study in the US. Under the financial terms of the agreement, BMS paid $650m to Eisai ($200m of which was to cover Eisai’s R&D
Sign In
Follow the stocks
